Phase 2 study of the g209-2M melanoma peptide vaccine and low-dose interleukin-2 in advanced melanoma: Cancer and Leukemia Group B 509901.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples